Our Pricing

Mounjaro Injections UK: Clinical Guide and Pricing

Published on: June 03, 2026

Finding mounjaro injections uk lowest price options requires comparing UK-registered pharmacies that offer transparent pricing and genuine licensed medication. At Cured Pharmacy, Mounjaro (tirzepatide) KwikPens start from £124.99, with all prices displayed upfront before your free clinical consultation with a UK prescriber.

How Mounjaro Tirzepatide Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing complementary effects on appetite regulation, insulin secretion, and energy expenditure.

In the landmark SURMOUNT-1 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. This dual-receptor mechanism distinguishes Mounjaro from earlier GLP-1-only treatments, with clinical data suggesting enhanced efficacy across weight loss metrics.

Tirzepatide works by slowing gastric emptying, reducing appetite signals in the hypothalamus, and improving insulin sensitivity. Most patients report decreased food cravings and earlier satiety after meals, though individual responses vary and require ongoing monitoring by a UK prescriber [2].

Mounjaro Dosing Schedule and Titration

All patients begin Mounjaro treatment at 2.5mg once weekly for the first four weeks, regardless of weight loss goals. This initial dose serves as a tolerance-building phase rather than a therapeutic dose, allowing your body to adjust to tirzepatide's effects on gastric motility and appetite hormones.

After the first month, your UK prescriber will typically increase the dose to 5mg weekly, with further escalations to 7.5mg, 10mg, 12.5mg, or 15mg at four-week intervals based on your response and tolerability [3]. The gradual titration schedule significantly reduces the incidence of gastrointestinal side effects compared to starting at higher doses.

Each KwikPen is a single-use, pre-filled injection device designed for subcutaneous administration in the abdomen, thigh, or upper arm. Most patients find the injection process straightforward after the first demonstration, and the once-weekly schedule offers greater convenience than daily injectable treatments.

What to Expect During Dose Escalation

Mild nausea and reduced appetite are common during the first week after each dose increase, typically resolving within 3-5 days as your body adapts. Eating smaller, more frequent meals and avoiding high-fat foods can minimise discomfort during titration phases. Your prescriber may slow the escalation schedule if side effects persist beyond the adjustment period.

Mounjaro vs Wegovy: Comparing UK Weight Loss Injections

Both Mounjaro and Wegovy are MHRA-licensed injectable treatments for weight management, but they differ in their receptor mechanisms and clinical trial outcomes. Wegovy contains semaglutide, a GLP-1 receptor agonist that achieved an average weight reduction of 14.9% over 68 weeks in the STEP-1 trial [4]. Mounjaro's dual GIP/GLP-1 action produced higher average weight loss in head-to-head comparisons, though individual responses vary considerably.

Saxenda, containing liraglutide, represents an earlier generation of daily GLP-1 injections. While effective for many patients, its daily administration schedule and lower average weight loss (8% in clinical trials) make it less comparable to the newer weekly formulations [5]. Some prescribers may recommend Saxenda for patients who prefer starting with a shorter-acting medication or who have specific contraindications to longer-acting formulations.

Your UK prescriber will consider your medical history, previous weight loss attempts, cardiovascular risk factors, and personal preferences when recommending between these options. All three medications require prescription-only dispensing and ongoing clinical monitoring throughout treatment.

Choosing Between Injectable Weight Loss Treatments

The choice between Mounjaro, Wegovy, and Saxenda depends on multiple clinical factors beyond average trial results. Patients with type 2 diabetes may benefit from Mounjaro's superior glycaemic control, whilst those with established cardiovascular disease may prioritise Wegovy's proven cardiovascular outcomes data. Cost considerations, injection frequency preferences, and individual side effect profiles all influence treatment selection during your consultation.

Common Side Effects and How to Manage Them

Gastrointestinal effects are the most frequently reported side effects with Mounjaro, affecting approximately 30-40% of patients during dose escalation [1]. Nausea, diarrhoea, constipation, and abdominal discomfort typically peak 1-3 days after injection and diminish as your body adapts to each new dose level.

Practical management strategies include eating smaller portions, avoiding lying down immediately after meals, staying well-hydrated, and temporarily reducing dietary fat intake. Most gastrointestinal symptoms resolve within 4-6 weeks of maintaining a stable dose, though a small percentage of patients require dose reduction or treatment discontinuation.

Rare but serious side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other diabetes medications). Severe persistent abdominal pain, especially radiating to the back, requires immediate medical assessment. Your UK prescriber will review your complete medical history to identify any contraindications before prescribing Mounjaro [3].

Who Can Use Mounjaro in the UK

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. NICE guidance recommends considering pharmacological weight management interventions when lifestyle modifications alone have not achieved adequate weight loss [6].

Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or previous serious hypersensitivity to tirzepatide. It should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment [3].

Your online consultation with a UK prescriber will assess your complete medical history, current medications, and treatment goals to determine suitability. All prescription weight loss medications require ongoing monitoring and should be used alongside dietary modifications and increased physical activity for optimal outcomes.

Pre-Treatment Health Assessment

Before starting Mounjaro, your prescriber will review your cardiovascular health, kidney function, history of pancreatitis or gallbladder disease, and any medications that may interact with tirzepatide. Patients taking insulin or sulfonylureas may require dose adjustments to prevent hypoglycaemia. Baseline weight, BMI, and weight-related health markers are documented to track treatment response over time.

Understanding Mounjaro Pricing and UK Availability

Mounjaro pricing in the UK varies significantly between pharmacies and dose strengths, with monthly costs typically increasing as you progress through the titration schedule to higher maintenance doses. At Cured Pharmacy, transparent pricing is displayed before your consultation begins, allowing you to understand the full cost commitment before speaking with a prescriber.

The mounjaro injections uk lowest price structure reflects several factors including wholesale acquisition costs, pharmacy dispensing fees, and prescriber consultation charges. Unlike some providers that advertise low entry prices but add hidden fees during checkout, Cured Pharmacy shows complete pricing upfront, with no consultation fees added to your medication cost.

UK supply of Mounjaro has improved significantly since its initial launch, though occasional temporary shortages of specific dose strengths can occur. Cured Pharmacy maintains relationships with multiple UK-licensed wholesalers to ensure consistent availability across the dose range. All Mounjaro supplied is genuine UK-licensed medication with full MHRA approval, never grey-market imports.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14881 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and weight loss outcomes depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.